Close X
Attorney Spotlight

After finishing her first year as an associate at Bass, Berry & Sims, find out what advice Margaret Dodson offers to new attorneys. Read more>

Search

Close X

Experience

Search our Experience

Experience Spotlight

On December 1, 2016, Parker Hannifin Corporation and CLARCOR Inc. announced that the companies have entered into a definitive agreement under which Parker will acquire CLARCOR for approximately $4.3 billion in cash, including the assumption of net debt. The transaction has been unanimously approved by the board of directors of each company. Upon closing of the transaction, expected to be completed by or during the first quarter of Parker’s fiscal year 2018, CLARCOR will be combined with Parker’s Filtration Group to form a leading and diverse global filtration business. Bass, Berry & Sims has served CLARCOR as primary corporate and securities counsel for 10 years and served as lead counsel on this transaction. Read more here.

CLARCOR
Close X

Thought Leadership

Enter your search terms in the relevant box(es) below to search for specific Thought Leadership.
To see a recent listing of Thought Leadership, click the blue Search button below.

Thought Leadership Spotlight

Blueprint for an IPO

Companies go public to raise capital to fuel growth, pay down debt and provide liquidity to shareholders. Although all issuers and offerings are different, the basic process of going public remains relatively constant. Blueprint for an IPO identifies the key players, details the process and identifies the obligations companies will face after going public.

Read now

AxelaCare CON Approved for West Tennessee Region

Client Type: Private Company

Bass, Berry & Sims served as lead counsel to AxelaCare Health Solutions LLC – a subsidiary of United Health Group – in its efforts to obtain a Certificate of Need (CON) to initiate homecare operations in 21 counties in and around metropolitan Memphis, Tennessee. The project was unanimously approved by state regulators. The addition of AxelaCare's services in West Tennessee will make highly specialized immune globulin infusion therapy available at home to seriously ill patients suffering from very rare cancers and chronic immunological and neurological disorders. Researchers across the United States use data collected via AxelaCare's proprietary patient care technology in a wide variety of clinical research.

AxelaCare specializes in specialty infusion therapy homecare services. Its nursing specialists have performed more than 44,000 infusion therapy sessions in recent years. AxelaCare has received the Joint Commission's "Gold Seal" of approval and is recognized for meeting the highest clinical standards in the industry.

You Also May Be Interested In:

Related Professionals

Related Services

Notice

Visiting, or interacting with, this website does not constitute an attorney-client relationship. Although we are always interested in hearing from visitors to our website, we cannot accept representation on a new matter from either existing clients or new clients until we know that we do not have a conflict of interest that would prevent us from doing so. Therefore, please do not send us any information about any new matter that may involve a potential legal representation until we have confirmed that a conflict of interest does not exist and we have expressly agreed in writing to the representation. Until there is such an agreement, we will not be deemed to have given you any advice, any information you send may not be deemed privileged and confidential, and we may be able to represent adverse parties.